Vaccines for RCC: Rationale and Clinical Update

Kidney Cancer Meeting Lyon, France 2015: Vaccines for RCC: Rationale and Clinical Update Hans Hammers M.D. / Ph.D.
Assistant Professor: Medical Oncology, Chemical Therapeutics
Johns Hopkins Kimmel Cancer Center

Advertisement Single Below Content

Vaccines for RCC: Rationale and Clinical Update

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Vaccines for RCC: Rationale and Clinical Update

Related Posts

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia